SEC Form 4 · accession 0001513905-17-000034

ELLIE MAE INC · ELLI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Dec 7, 2017

Accepted (ET)

Dec 11, 2017 · 8:56 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001122388

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 7, 2017	M	300	$24.93	A	114,633	D
Common Stock^F1	Dec 7, 2017	S	300	$89.45	D	114,333	D
Common Stock^F1	Dec 7, 2017	M	241	$24.93	A	114,574	D
Common Stock^F1,F2	Dec 7, 2017	S	241	$88.5502	D	114,333	D
Common Stock^F1	Dec 7, 2017	M	1,082	$46.24	A	115,415	D
Common Stock^F1,F2	Dec 7, 2017	S	1,082	$88.5502	D	114,333	D
Common Stock^F1	Dec 11, 2017	M	589	$46.24	A	114,922	D
Common Stock^F1	Dec 11, 2017	S	589	$89.6111	D	114,333	D
Common Stock	holding	—	—		—	79,347	I	by Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F1,F4,F3	$24.93	Dec 7, 2017	M	300	D	—	Feb 5, 2024	Common Stock	300	1,699	D
Non-Qualified Stock Option (right to buy)^F1,F4,F3	$24.93	Dec 7, 2017	M	241	D	—	Feb 5, 2024	Common Stock	241	1,458	D
Non-Qualified Stock Option (right to buy)^F1,F4,F5	$46.24	Dec 7, 2017	M	1,082	D	—	Feb 11, 2025	Common Stock	1,082	8,838	D
Non-Qualified Stock Option (right to buy)^F1,F4,F5	$46.24	Dec 11, 2017	M	589	D	—	Feb 11, 2025	Common Stock	589	8,249	D

F1The exercise and sale of these stock options was completed pursuant to the Rule 10b5-1 trading plan adopted by Jonathan H. Corr.
F2The price reported is a weighted average price. The shares were sold in multiple transactions ranging from $88.4400 to $88.7200, inclusive. The reporting person undertakes to provide to Ellie Mae, Inc., any security holder of Ellie Mae, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3Option vests with respect to 25% of the shares subject thereto on February 5, 2015, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on February 5, 2018.
F4The reported transaction is a grant of a derivative security, in which we have left column 8 blank, and have reported the exercise or conversion price of the derivative security in column 2.
F5Option vests with respect to 25% of the shares subject thereto on February 11, 2016, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on February 11, 2019.